Citizens Downgrades Astria Therapeutics (ATXS) to Market Perform

Citizens analyst Jonathan Wolleben downgraded Astria Therapeutics (NASDAQ: ATXS) from Market Outperform to Market Perform.

The analyst comments: "BioCryst is scooping up Astria’s navenibart to expand its HAE portfolio beyond daily oral Orladeyo to a potential best-in-class injectable plasma kallikrein inhibitor delivered every three or six months; we downgrade our rating on Astria from Market Outperform to Market Perform, and we view it as highly likely that the transaction will close as announced."

For an analyst ratings summary and ratings history on Astria Therapeutics click here. For more ratings news on Astria Therapeutics click here.

Shares of Astria Therapeutics closed at $11.61 yesterday.

You May Also Be Interested In

• Morgan Stanley Downgrades Cosmos Pharmaceuticals Corp. (3349:JP) (CSMYF) to Equalweight
• Cummins India (KKC:IN) PT Raised to INR5,700 at Kotak
• Nippon Paint Said To Offer $8.6 Billion For Akzo's Paint Arm - Bloomberg